<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101638820</journal-id><journal-id journal-id-type="pubmed-jr-id">42950</journal-id><journal-id journal-id-type="nlm-ta">J Prev Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Prev Alzheimers Dis</journal-id><journal-title-group><journal-title>The journal of prevention of Alzheimer's disease</journal-title></journal-title-group><issn pub-type="ppub">2274-5807</issn><issn pub-type="epub">2426-0266</issn></journal-meta><article-meta><article-id pub-id-type="pmid">40107919</article-id><article-id pub-id-type="pmc">PMC12094269</article-id><article-id pub-id-type="doi">10.1016/j.tjpad.2025.100117</article-id><article-id pub-id-type="manuscript">NIHMS2073911</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Association of dietary fatty acids with longitudinal change in plasma-based biomarkers of Alzheimer&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hoost</surname><given-names>Serena S.</given-names></name><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Honig</surname><given-names>Lawrence S.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Min Suk</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Bahl</surname><given-names>Aanya</given-names></name><xref rid="A1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Annie J.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Sanchez</surname><given-names>Danurys</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Reyes-Dumeyer</surname><given-names>Dolly</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Lantigua</surname><given-names>Rafael A.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Dage</surname><given-names>Jeffrey L.</given-names></name><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Brickman</surname><given-names>Adam M.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Manly</surname><given-names>Jennifer J.</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Mayeux</surname><given-names>Richard</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A3" ref-type="aff">c</xref><xref rid="A4" ref-type="aff">d</xref><xref rid="FN1" ref-type="author-notes">1</xref></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Yian</given-names></name><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A3" ref-type="aff">c</xref><xref rid="A4" ref-type="aff">d</xref><xref rid="FN1" ref-type="author-notes">1</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>a</label> Taub Institute for Research on Alzheimer&#x02019;s Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY, 10032, USA</aff><aff id="A2"><label>b</label> G.H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, New York, 10032, USA</aff><aff id="A3"><label>c</label> Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, 710 West 168th Street, New York, New York, 10032, USA</aff><aff id="A4"><label>d</label> Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, New York, 10032, USA</aff><aff id="A5"><label>e</label> Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, 630 West 168th Street, New York, New York, 10032, USA</aff><aff id="A6"><label>f</label> Stark Neurosciences Research Institute, Suite 414, Indiana University School of Medicine, 320 West 15th Street, Indianapolis, Indiana, 46202, USA</aff><author-notes><fn fn-type="equal" id="FN1"><label>1</label><p id="P1">The authors contributed equally to this work.</p></fn><corresp id="CR1"><label>*</label> Corresponding author at: Columbia University Irving Medical Center, 622 W 168th St., pH 18th floor, New York, NY, 10032. <email>yg2121@cumc.columbia.edu</email> (Y. Gu).</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>25</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>18</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><volume>12</volume><issue>5</issue><fpage>100117</fpage><lpage>100117</lpage><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>)</license-p></license></permissions><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P2">Elevated intake of omega-3 polyunsaturated fatty acids is linked to a reduced risk of dementia in some prospective studies. However, few studies have examined the relationship between nutrient intake and plasma biomarkers of Alzheimer&#x02019;s disease.</p></sec><sec id="S2"><title>Objectives:</title><p id="P3">We explored whether omega-3, omega-6, and monounsaturated fat intakes were associated with changes in plasma biomarkers of Alzheimer&#x02019;s disease over time.</p></sec><sec id="S3"><title>Design:</title><p id="P4">The Washington Heights-Inwood Columbia Aging Project is a prospective cohort study (1994&#x02013;2021); the data set used here includes a mean follow-up of 7.0 years.</p></sec><sec id="S4"><title>Setting:</title><p id="P5">Community-based in New York City.</p></sec><sec id="S5"><title>Participants:</title><p id="P6">599 dementia-free individuals at baseline who completed a 61-item food frequency questionnaire and had biomarkers measured in plasma from at least two different time points.</p></sec><sec id="S6"><title>Measurements:</title><p id="P7">Fatty acid intake tertiles were computed from participant-completed 61-item Willett semi-quantitative food frequency questionnaires (Channing Laboratory, Cambridge, Massachusetts) obtained once at their baseline visit. Plasma-based biomarker assays were performed, using the single molecule array technology Quanterix Simoa HD-X platform, at baseline and follow-up visits. Generalized Estimating Equations (GEE) models were used to evaluate the association between baseline nutrient intake tertile and changes in biomarkers including phospho-tau181, amyloid-beta 42/40 ratio, phospho-tau181/amyloid-beta42 ratio, glial fibrillary acidic protein, neurofilament light chain, and two biomarker patterns derived from Principal Component Analysis (PCA1 and PCA2), with higher scores indicating a high level of neurodegeneration and low level of Alzheimer&#x02019;s disease burden, respectively). Models were adjusted for age, sex, race/ethnicity, education, and calculated total energy intake initially, and additionally for cerebrovascular risk factors.</p></sec><sec id="S7"><title>Results:</title><p id="P8">Higher baseline omega-3 intake tertile was associated with lesser decline in PCA2 (<italic toggle="yes">&#x003b2;</italic> = 0.221, <italic toggle="yes">p</italic> &#x0003c; 0.001) and amyloid-beta 42/40 ratio (<italic toggle="yes">&#x003b2;</italic> = 0.022, <italic toggle="yes">p</italic> = 0.003), and a lesser rise in phospho-tau181 (<italic toggle="yes">&#x003b2;</italic> = &#x02212;0.037, <italic toggle="yes">p</italic> = 0.001) Higher omega-6 intake tertile was linked to a lesser rise in phospho-tau181 (<italic toggle="yes">&#x003b2;</italic> = &#x02212;0.050, <italic toggle="yes">p</italic> &#x0003c; 0.001) and glia fibrillary acidic protein (<italic toggle="yes">&#x003b2;</italic> = &#x02212;0.028, <italic toggle="yes">p</italic> = 0.002). Most associations persisted after adjusting for cardiovascular risk factors.</p></sec><sec id="S8"><title>Conclusions:</title><p id="P9">Higher relative baseline intake of omega-3 and omega-6 fatty acids is associated with lesser progression of blood-based biomarkers of Alzheimer&#x02019;s disease. Consuming healthy fatty acids may help prevent accumulation of Alzheimer&#x02019;s disease-related pathological changes.</p></sec></abstract><kwd-group><kwd>Blood-based biomarker</kwd><kwd>Diet</kwd><kwd>Omega-3</kwd><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Amyloid</kwd></kwd-group></article-meta></front><body><sec id="S9"><label>1.</label><title>Introduction</title><p id="P10">Accumulating evidence suggests the importance of dietary factors in preventing Alzheimer&#x02019;s disease (AD) [<xref rid="R1" ref-type="bibr">1</xref>]. Polyunsaturated fatty acids (PUFAs) stand out for their critical roles in brain structure and function and their consistent association with reduced risk of AD in epidemiological studies [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>]. Individuals with higher dietary intake of omega-3 (O-3) PUFAs, found most richly in fish and seafood [<xref rid="R4" ref-type="bibr">4</xref>], are less likely to develop cognitive decline and AD in observational studies [<xref rid="R5" ref-type="bibr">5</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref>], including ours [<xref rid="R7" ref-type="bibr">7</xref>]. These associations raise the question of whether these key nutrients slow the progression of AD pathophysiology in the pre-clinical phase, when individuals may derive the greatest benefit from targeted lifestyle modifications. In AD, changes in the brain reflected in body fluid biomarkers, or increased amyloid burden on positron emission tomography (PET), may precede cognitive impairment by as many as 15 years [<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>].</p><p id="P11">Blood-based biomarkers provide an accessible way to identify individuals at risk of developing AD in large cohorts [<xref rid="R12" ref-type="bibr">12</xref>], and they allow for serial measurements tracking the accumulation of AD pathology over time [<xref rid="R13" ref-type="bibr">13</xref>]. As such, blood-based biomarkers may provide insight into the relationship between diet and the progression of AD pathophysiology before symptom onset. However, the association between dietary fatty acid intake and AD biomarkers, especially blood-based biomarkers, has been evaluated in few studies so far [<xref rid="R14" ref-type="bibr">14</xref>&#x02013;<xref rid="R19" ref-type="bibr">19</xref>].</p><p id="P12">We chose to evaluate whether high intake of key nutrients from food would predict a lesser change in plasma AD biomarkers over time in participants of a multi-ethnic cohort of older adults who were dementia-free at baseline. We included dietary intake of O-3 and omega-6 (O-6) PUFAs and monounsaturated fatty acids (MUFAs) measured at baseline. We included phosphorylated tau 181 (P-tau181), amyloid beta (A<italic toggle="yes">&#x003b2;</italic>) 42/40 ratio, P-tau181/A<italic toggle="yes">&#x003b2;</italic>42 ratio, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as AD-related biomarkers. We also included the first two biomarker patterns previously derived from principal component analysis (PCA1, PCA2) of the latter four biomarkers [<xref rid="R20" ref-type="bibr">20</xref>]. The PCA1 pattern has elevated NfL and GFAP, reflecting neurodegeneration and neuroinflammation, while the PCA2 pattern contains elevated A<italic toggle="yes">&#x003b2;</italic>42/40 and low P-tau181/A<italic toggle="yes">&#x003b2;</italic>42, and thus is more AD-specific [<xref rid="R20" ref-type="bibr">20</xref>]. In the prior study, individuals who developed dementia or MCI had faster decrease in PCA2 score compared to those who remained cognitively normal during follow-up [<xref rid="R20" ref-type="bibr">20</xref>]. We hypothesized that individuals with the highest relative O-3, O-6 and MUFA intake would have lesser progression of AD pathophysiology over time reflected in biomarker levels.</p><p id="P13">To evaluate whether a reduced burden of cardiovascular disease mediated the association, we included a final model adjusting for a cardio-cerebrovascular risk factor (CVRF) score. This score was previously derived in our cohort based on body mass index and history of heart disease, hypertension and diabetes. We performed a secondary analysis using individual O-3 fatty acids, including eicosapentaenoic (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA).</p></sec><sec id="S10"><label>2.</label><title>Methods</title><sec id="S11"><label>2.1.</label><title>Cohort and clinical diagnosis</title><p id="P14">The Washington Heights-Inwood Columbia Aging Project (WHICAP) is a multiethnic, community-based prospective cohort study about risk factors for dementia. This study was approved by the institutional review boards of Columbia University. All participants provided written informed consent.</p><p id="P15">The study design has been described in detail elsewhere [<xref rid="R21" ref-type="bibr">21</xref>]. Briefly, WHICAP participants are individuals 65 years and older, residing in northern Manhattan, who speak English or Spanish. There have been three major waves of enrollment, beginning in 1992 (93 participants in the current study), 1999 (44 participants), and 2009 (462 participants).</p><p id="P16">Each visit was comprised of a structured interview of demographics, lifestyle information, medical and neurological history, followed by a standardized physical exam, a neurological exam, and neuropsychiatric testing. Participants completed a 61-item Willett semi-quantitative food frequency questionnaire (SFFQ) (Channing Laboratory, Cambridge, Massachusetts) at their baseline visit only. Race and ethnicity were reported and coded using standardized criteria [<xref rid="R22" ref-type="bibr">22</xref>]. At the baseline and each subsequent visit, blood was drawn. Participants returned for follow-up visits every 18 to 24 months.</p><p id="P17">A diagnostic consensus conference for each visit was attended by at least one neurologist and one neuropsychologist with experience in AD. Using neuropsychological testing and evidence of functional impairment, a clinical diagnosis of probable or possible AD was assigned based on the National Institute on Aging-Alzheimer&#x02019;s Association criteria [<xref rid="R23" ref-type="bibr">23</xref>]. Evaluators were blinded to previous diagnoses for follow-up visits.</p></sec><sec id="S12"><label>2.2.</label><title>Inclusion and exclusion criteria</title><p id="P18">For the current study, we selected individuals without dementia at baseline who completed the SFFQ at their initial visit and had plasma biomarkers measured during at least two different visits (<xref rid="SD1" ref-type="supplementary-material">Supplementary eFigure 1</xref>). To be included, participants had to have biomarkers measured at least at 2 or 3 visits. For one participant with 4 visits, the last one was excluded from the analysis (<xref rid="SD1" ref-type="supplementary-material">eFigure 1</xref>). We excluded 6 participant visits in which there were outliers (|Z-score| &#x0003e; 3) in any of the chosen plasma biomarkers. We excluded 2 participants for outliers at the baseline visit and 1 participant for an insufficient total number of blood samples (&#x0003c;2) after the removal of a follow-up visit which contained an outlier. In total, 10 participant visits were excluded from the analysis (<xref rid="SD1" ref-type="supplementary-material">eFigure 1</xref>).</p></sec><sec id="S13"><label>2.3.</label><title>Plasma collection and plasma biomarkers measurement</title><p id="P19">At the baseline and each subsequent visit, blood samples were collected by standard venipuncture in dipotassium ethylenediaminetetraacetic acid tubes, as previously described [<xref rid="R12" ref-type="bibr">12</xref>]. Study visits occurred in the morning or afternoon and participants were not required to fast. Briefly, plasma biomarker assays were performed using the single molecule array technology Quanterix Simoa (single molecule array) [<xref rid="R22" ref-type="bibr">22</xref>] HD-X platform (Quanterix, Billerica, MA, USA). Samples were diluted and assayed in duplicate using three Quanterix kits: Neurology 3-Plex A (catalog No. 101,995) for A<italic toggle="yes">&#x003b2;</italic>42 and A<italic toggle="yes">&#x003b2;</italic>40; P-tau181 V2 Advantage (catalog No. 103,714) for Tau phosphorylated at threonine 181 (P-tau181); and Neurology 2-Plex B (catalog No. 103,520) for NfL and GFAP. Quantification functional lower limits for these analytes were 2.7pg/mL for A<italic toggle="yes">&#x003b2;</italic>40, 0.6 pg/mL for A<italic toggle="yes">&#x003b2;</italic>42, 0.3 pg/mL for P-tau181, 0.8 pg/mL for NfL, and 16.6 pg/mL for GFAP. Mean sample coefficient of variation for each biomarker, calculated from the duplicate samples, was less than 5%. Ratios of A<italic toggle="yes">&#x003b2;</italic>42/A<italic toggle="yes">&#x003b2;</italic>40 and P-tau181/A<italic toggle="yes">&#x003b2;</italic>42 were calculated.</p></sec><sec id="S14"><label>2.4.</label><title>Nutrients</title><p id="P20">The SFFQs have been used and validated in the elderly [<xref rid="R24" ref-type="bibr">24</xref>] and in our cohort [<xref rid="R25" ref-type="bibr">25</xref>]. Daily intake of nutrients in miligrams was computed by multiplying the consumption frequency of each food by the content of the specified nutrient [<xref rid="R26" ref-type="bibr">26</xref>]. We excluded nutrient intake from supplements to focus on the effects of naturally occurring dietary sources [<xref rid="R27" ref-type="bibr">27</xref>], minimize variability from inconsistent supplement use, and avoid potential biases such as reverse causation and misreporting. For this analysis, we used the residuals of the linear regression of total energy intake on the intake of each nutrient to avoid confounding by total energy intake. The residual of each nutrient was further categorized into tertiles.</p><p id="P21">A score indicating adherence to the Mediterranean diet (MeDi) [<xref rid="R28" ref-type="bibr">28</xref>] was used as an indicator of overall dietary quality. One point each was given for higher-than-median intake of food in six beneficial categories (fruits, vegetables, legumes, cereals, and fish). One point was given for higher-than-median ratio of monounsaturated to saturated fats. One point each was given for lower-than-median intake of two detrimental food categories (meat, dairy). One point was given for mild to moderate alcohol consumption (0&#x02013;30<italic toggle="yes">g</italic>/day)). Overall, the MeDi score ranged 0&#x02013;9, with a higher score indicating better adherence.</p></sec><sec id="S15"><label>2.5.</label><title>Covariates</title><p id="P22">The CVRF score was created in the WHICAP cohort as previously described [<xref rid="R29" ref-type="bibr">29</xref>], using principal component analysis of body mass index (measured at in person visits) and self-reported hypertension, diabetes and heart disease. The validity of self-reported vascular risk factors has been confirmed in our cohort [<xref rid="R30" ref-type="bibr">30</xref>]. Education was recorded in years based on self-report. We used <italic toggle="yes">APOE &#x003b5;</italic>4 genotype dichotomously as the presence (either 1 or 2) or absence of <italic toggle="yes">&#x003b5;</italic>4 alleles. Charlson Comorbidity Index [<xref rid="R31" ref-type="bibr">31</xref>] was assessed at the initial visit only.</p></sec><sec id="S16"><label>2.6.</label><title>Statistical analyses</title><p id="P23">We compared descriptive variables across nutrient intake tertiles (low, middle, high) using one-way ANOVA for continuous variables and Chi-Square for categorical variables. For variables that differed according to nutrient intake tertile (<italic toggle="yes">p</italic> &#x0003c; 0.05), we performed a post-hoc analysis to determine which levels of intake (low, middle or high) differed from one another. We used Tukey Honestly Significant Differences for continuous variables and Chi Square for categorical variables.</p><p id="P24">In cross-sectional analysis, we evaluated the association between nutrient intake tertile and biomarker concentrations at baseline using Generalized Linear Models. In longitudinal analysis, we evaluated the effect of the interaction between nutrient intake tertiles and the passage of time (in number of visits) on biomarker concentrations, using Generalized Estimating Equations (GEE) with an autoregressive correlation structure. Participants with missing values were eliminated from the models. For both cross-sectional and longitudinal analyses, we included three models each. Model 1 was adjusted for total energy intake only. Model 2 was adjusted for total energy intake, age at baseline, sex, ethnicity, education and storage time. For Model 2, we included a trend analysis in which nutrient intake tertile was coded as a continuous variable [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>]. Model 3 was adjusted for Model 2 covariates and CVRF score.</p><p id="P25">In secondary analysis, we evaluated the effect of the individual O-3 PUFAs EPA, DHA, and DPA on longitudinal biomarker concentrations. We evaluated the interaction sex <sup>&#x02217;</sup> nutrient intake tertile on baseline biomarker concentration. We also evaluated whether the associations we identified in the primary analysis (Model 2) remained significant after adjusting for MeDi adherence and the presence of <italic toggle="yes">APOE &#x003b5;4</italic>, and after adjusting for the Charlson Comorbidity Index. We repeated Model 1 and Model 2 of the primary analysis using time in years. Lastly, we repeated the analysis with mixed effects models with random effects for repeated measures.</p><p id="P26">All p-values for trend and continuous analyses were adjusted for multiple comparisons using the Benjamini &#x00026; Hochberg false discovery rate (FDR) method. Results were considered to be statistically significant when FDR-adjusted P value was &#x0003c; 0.05.</p></sec></sec><sec id="S17"><label>3.</label><title>Results</title><sec id="S18"><label>3.1.</label><title>Study participants</title><p id="P27">599 participants were included in the current study (<xref rid="SD1" ref-type="supplementary-material">eFigure 1</xref>). 52 participants had biomarkers measured at 2 visits (one baseline and one follow up visit), and 547 participants had biomarkers measured at 3 visits. Follow-up time ranged from 1.5 to 22.9 years, with a mean of 7.0 years. Participants had attained on average 11.3 years of education at baseline and had a MeDi adherence score of 4.5 (<xref rid="T1" ref-type="table">Table 1</xref>). Twenty-five percent had at least one APOE &#x003b5;4 allele, and 13% developed dementia during the follow up period (<xref rid="T1" ref-type="table">Table 1</xref>). The mean Charlson Comorbidity Index score was 2.2 (<xref rid="T1" ref-type="table">Table 1</xref>).</p></sec><sec id="S19"><label>3.2.</label><title>Descriptive analyses</title><p id="P28">At baseline, participants with O-3, O-6 and MUFA intakes in the high tertiles were younger (<xref rid="T1" ref-type="table">Table 1</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary eTables 1</xref>&#x02013;<xref rid="SD1" ref-type="supplementary-material">2</xref>). Those with intake in higher tertiles of all three fatty acids had more years of education (<xref rid="T1" ref-type="table">Table 1</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary eTables 1</xref>&#x02013;<xref rid="SD1" ref-type="supplementary-material">2</xref>). O-6 PUFA and MUFA intake tertile varied by ethnicity (<xref rid="SD1" ref-type="supplementary-material">Supplementary eTables 1</xref>&#x02013;<xref rid="SD1" ref-type="supplementary-material">2</xref>), with non-Hispanic White and non-Hispanic Black individuals with intake in higher tertiles than Hispanic individuals. Individuals with O-3 intake in the high tertile consumed less total energy than those with intake in the low tertile (<xref rid="T1" ref-type="table">Table 1</xref>), whereas there was not a consistent trend for O-6 or MUFA intake tertile (<xref rid="SD1" ref-type="supplementary-material">eTables 1</xref>&#x02013;<xref rid="SD1" ref-type="supplementary-material">2</xref>). Participants with high tertile O-3 intakes had higher MeDi adherence (<xref rid="T1" ref-type="table">Table 1</xref>), but those with high tertile MUFA intakes had lower adherence compared to those with low tertile intakes (<xref rid="SD1" ref-type="supplementary-material">eTable 2</xref>). Participants did not vary in their MeDi adherence by O-6 tertile (<xref rid="SD1" ref-type="supplementary-material">eTable 2</xref>). About 0.5%, 40%, and 100% of the participants with O-3 intakes in the low, middle, and high tertiles consumed 2 or more portions of fish per week (<xref rid="T1" ref-type="table">Table 1</xref>). Those with high tertile O-6 and MUFA intakes were less likely to develop dementia at a follow up visit compared to those with low tertile intakes (<xref rid="SD1" ref-type="supplementary-material">Supplementary eTables 1</xref>&#x02013;<xref rid="SD1" ref-type="supplementary-material">2</xref>). Those with O-6 intakes in the high tertile had lower BMI and lower Charlson Comorbidity Index compared to those with intakes in the low tertile (<xref rid="SD1" ref-type="supplementary-material">eTable 2</xref>).</p></sec><sec id="S20"><label>3.3.</label><title>Cross-sectional analyses</title><p id="P29">At baseline, there were numeric differences, although without statistical significance in trend analysis, in biomarker levels by nutrient intake tertiles, with higher O-3 having lower levels of GFAP, NfL, and PCA1 (<xref rid="F1" ref-type="fig">Fig. 1</xref>, <xref rid="SD1" ref-type="supplementary-material">eTable 3</xref>).</p></sec><sec id="S21"><label>3.4.</label><title>Longitudinal analyses</title><p id="P30">In our study participants, P-tau181 (<italic toggle="yes">&#x003b2;</italic>= 0.048 log-transformed pg/ml per visit, p-adjusted &#x0003c; 0.001), GFAP (<italic toggle="yes">&#x003b2;</italic>= 0.063, p-adjusted &#x0003c; 0.001) and NfL levels (<italic toggle="yes">b</italic> = 0.076, p-adjusted &#x0003c; 0.001) increased across subsequent visits while A<italic toggle="yes">&#x003b2;</italic>42/40 ratio (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.153, p-adjusted &#x0003c; 0.001) and P-tau181/A<italic toggle="yes">&#x003b2;</italic>42 ratio (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.017, p-adjusted = 0.024) decreased. Neither PCA1 (<italic toggle="yes">&#x003b2;</italic>= 0.248, p-adjusted = 0.20) nor PCA2 score (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.007, p-adjusted = 0.746) changed significantly over time.</p><p id="P31">Individuals with high tertile O-3 intakes had a lesser increase in P-tau181 level (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.037 log-transformed pg/ml, <italic toggle="yes">p</italic> = 0.001, p-trend = 0.006), and lesser decrease in A<italic toggle="yes">&#x003b2;</italic>42/40 ratio (<italic toggle="yes">&#x003b2;</italic>= 0.022, <italic toggle="yes">p</italic> = 0.003, p-trend = 0.013) across subsequent visits compared to those with low tertile intakes (<xref rid="F2" ref-type="fig">Fig. 2</xref>, <xref rid="T2" ref-type="table">Table 2</xref>). They also had a lesser decrease in PCA2 score (<italic toggle="yes">b</italic> = 0.221, <italic toggle="yes">p</italic> &#x0003c; 0.001, p-trend = 0.001) over time (<xref rid="F3" ref-type="fig">Fig. 3</xref>, <xref rid="T2" ref-type="table">Table 2</xref>). After adjusting for CVRF score, the associations of O-3 PUFA tertile with PCA2 score (<italic toggle="yes">&#x003b2;</italic>= 0.168, <italic toggle="yes">p</italic> = 0.010) and P-tau181 level (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.030, <italic toggle="yes">p</italic> = 0.027) persisted. However, the association with A<italic toggle="yes">&#x003b2;</italic>42/40 ratio was no longer significant (<italic toggle="yes">&#x003b2;</italic>= 0.013, <italic toggle="yes">p</italic> = 0.097) (<xref rid="T2" ref-type="table">Table 2</xref>).</p><p id="P32">Individuals with O-6 intakes in middle (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.037, <italic toggle="yes">p</italic> = 0.003) and high (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.050, <italic toggle="yes">p</italic> &#x0003c; 0.001) tertiles had a lesser increase in P-tau181 concentration over time, compared to those with intakes in the low tertile (p-trend &#x0003c; 0.001) (<xref rid="F2" ref-type="fig">Fig. 2</xref>, <xref rid="T2" ref-type="table">Table 2</xref>). These associations remained significant after adjusting for CVRF score (middle, <italic toggle="yes">&#x003b2;</italic>= &#x02212;0.033, <italic toggle="yes">p</italic> = 0.025; high, <italic toggle="yes">&#x003b2;</italic>= &#x02212;0.046, <italic toggle="yes">p</italic> = 0.002) (<xref rid="T2" ref-type="table">Table 2</xref>). Those with O-6 intakes in the high tertile also had a lesser increase in GFAP level (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.028, <italic toggle="yes">p</italic> = 0.002, p-trend = 0.008) (<xref rid="F2" ref-type="fig">Fig. 2</xref>, <xref rid="T2" ref-type="table">Table 2</xref>), even after adjusting for CVRF score (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.028, <italic toggle="yes">p</italic> = 0.009) (<xref rid="T2" ref-type="table">Table 2</xref>).</p></sec><sec id="S22"><label>3.5.</label><title>Secondary analysis comparing subtypes of O-3 PUFAs</title><p id="P33">Compared to participants with low tertile intakes of EPA, those in with high tertile intakes had a lesser increase in P-tau181 level (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.033, <italic toggle="yes">p</italic> = 0.004, p-trend = 0.016) and a lesser decrease in PCA2 score over time (<italic toggle="yes">&#x003b2;</italic>= 0.205, <italic toggle="yes">p</italic> &#x0003c; 0.001, <italic toggle="yes">p</italic> = 0.002) (<xref rid="SD1" ref-type="supplementary-material">eTable 4</xref>). Those with middle (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.028, <italic toggle="yes">p</italic> = 0.034) and high (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.037, <italic toggle="yes">p</italic> = 0.004) tertile DPA intakes had a lesser rise in P-tau181 compared to those with low tertile intakes (p-trend = 0.016) (<xref rid="SD1" ref-type="supplementary-material">eTable 4</xref>). Those with high tertile intakes had a lesser decline in A<italic toggle="yes">&#x003b2;</italic>42/40 (<italic toggle="yes">&#x003b2;</italic>= 0.023, <italic toggle="yes">p</italic> = 0.001, p-trend = 0.009) compared to those with low tertile intakes (<xref rid="SD1" ref-type="supplementary-material">eTable 4</xref>). Those with middle (<italic toggle="yes">&#x003b2;</italic>= 0.155, <italic toggle="yes">p</italic> = 0.010) and high (<italic toggle="yes">&#x003b2;</italic>= 0.226, <italic toggle="yes">p</italic> &#x0003c; 0.001) tertile DPA intakes had a lesser decrease in PCA2 score over time (p-trend = 0.001), compared to those with low tertile intakes (<xref rid="SD1" ref-type="supplementary-material">eTable 4</xref>). Lastly, those with high tertile DHA intakes had a lesser rise in P-tau181 level (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.030, <italic toggle="yes">p</italic> = 0.009, p-trend = 0.027) and a lesser decrease in PCA2 score (<italic toggle="yes">&#x003b2;</italic>= 0.169, <italic toggle="yes">p</italic> = 0.003, p-trend = 0.015), compared to those with low tertile intakes (<xref rid="SD1" ref-type="supplementary-material">eTable 4</xref>).</p></sec><sec id="S23"><label>3.6.</label><title>Sensitivity analyses</title><p id="P34">Models 1 and 2 of the primary analysis were repeated with time measured in years and (residuals of) continuous nutrient intake in mg/day. Higher O-3 intake was associated with a lesser change in P-tau 181 level and PCA2 score over time (<xref rid="SD1" ref-type="supplementary-material">eTable 5</xref>). However, O-3 PUFA intake was not associated with change in A<italic toggle="yes">&#x003b2;</italic>42/40 ratio, and O-6 PUFA intake was not significantly associated with biomarkers (<xref rid="SD1" ref-type="supplementary-material">eTable 5</xref>). Repeating the analysis using mixed effects models with random effects for repeated measures yielded consistent results (<xref rid="SD1" ref-type="supplementary-material">eTable 6</xref>), and all associations identified in Model 2 of the original analysis (<xref rid="T2" ref-type="table">Table 2</xref>) remained significant.</p><p id="P35">Higher MeDi adherence was associated with lower baseline PCA1 score (<italic toggle="yes">p</italic> = 0.046) when adjusting for total energy intake only, but not after adjusting for other covariates, including baseline age, sex, ethnicity, education and storage time (<xref rid="SD1" ref-type="supplementary-material">eTable 7</xref>). Higher MeDi score was numerically associated with lesser decrease in PCA2 score over time, but this was not statistically significant after adjustment for 7 comparisons (<xref rid="SD1" ref-type="supplementary-material">eTable 7</xref>). The differences in longitudinal change in biomarkers in the primary analysis (Model 2, <xref rid="T2" ref-type="table">Table 2</xref>) persisted after additionally adjusting for MeDi score and <italic toggle="yes">APOE</italic> &#x003b5;4 status (data not shown).</p><p id="P36">When excluding participants with incident dementia, we found similar results in longitudinal analysis, except that the middle (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.101, <italic toggle="yes">p</italic> = 0.035) and high (<italic toggle="yes">&#x003b2;</italic>= &#x02212;0.130, <italic toggle="yes">p</italic> = 0.004) tertile O-6 intakes were additionally associated with lesser increase in PCA1 score over time compared to low tertile intake (p-trend = 0.022) (<xref rid="SD1" ref-type="supplementary-material">Supplementary eTable 8</xref>). Adjustment for the Charlson Comorbidity Index did not alter the results (<xref rid="SD1" ref-type="supplementary-material">eTable 9</xref>). Evaluating the interaction sex <sup>&#x02217;</sup> nutrient tertile on baseline biomarker concentrations did not show a significant difference between men and women (<xref rid="SD1" ref-type="supplementary-material">eTable 10</xref>).</p></sec></sec><sec id="S24"><label>4.</label><title>Discussion</title><p id="P37">In a multi-ethnic community-based cohort of older adults without baseline dementia, individuals with high tertile O-3 intake had a lesser progression of AD-related biomarkers across subsequent visits compared to those with low intake, including a lesser decrease in PCA2 score, a lesser increase in P-tau181 level and a lesser decrease in A<italic toggle="yes">&#x003b2;</italic>42/40 ratio. In addition, those with high O-6 intake tertile had a lesser increase in P-tau181 and GFAP levels compared to those with low intake tertile. Most of these relationships persisted after adjusting for cardiovascular risk factor score.</p><p id="P38">The results suggest that individuals with higher relative intakes of both O-3 and O-6 PUFAs had slower progression of AD pathophysiology over time. This protective association corresponded mostly to AD-specific changes (A<italic toggle="yes">&#x003b2;</italic>42/40 and P-tau181) rather than less specific markers of nervous system injury (GFAP and NfL). This distinction underscores the possibility that PUFA, especially O-3, might modulate pathological processes central to AD, such as amyloid plaque formation and tau pathology, rather than general neuronal damage or inflammation. Associations of each of the individual O-3 PUFAs (EPA, DPA and DHA) with biomarkers were similar to those identified for O-3 in the primary analysis, and they suggest that the individual PUFAs have similar relationships with AD biomarkers. It is unclear why individuals with the highest O-3 intake had a longitudinal increase in PCA2 score, increase in A<italic toggle="yes">&#x003b2;</italic>42/40 ratio (component 1 of PCA2 score) and decrease P-tau181, but no significant change in P-tau181/A<italic toggle="yes">&#x003b2;</italic>42 (component 2 of PCA2 score). However, the numeric change in P-tau181/A<italic toggle="yes">&#x003b2;</italic>42 associated with high tertile O-3 intake was in the expected direction. Further studies could explore the temporal sequence of biomarker changes in response to O-3 intake.</p><p id="P39">We hypothesized that dietary intake of key nutrients would reduce risk of AD, reflected in a lesser increase in biomarker levels, via a reduced burden of vascular risk factors. A growing body of literature suggests that vascular comorbidities may influence the levels of plasma biomarkers [<xref rid="R32" ref-type="bibr">32</xref>&#x02013;<xref rid="R34" ref-type="bibr">34</xref>]. In one biracial cohort, individuals with diabetes had lower GFAP levels, those with history of stroke had higher NfL, and those with chronic kidney disease had higher NfL and lower P-tau181 [<xref rid="R32" ref-type="bibr">32</xref>]. Other studies have shown variation in white matter hyperintensity, a marker for microvascular disease, by P-tau181, P-tau217 [<xref rid="R35" ref-type="bibr">35</xref>] and GFAP levels [<xref rid="R36" ref-type="bibr">36</xref>]. EPA and DHA were associated with reduced risk of cardiovascular disease in prospective cohort studies [<xref rid="R37" ref-type="bibr">37</xref>]. In prospective cohorts and randomized controlled trials, plant-based oils enriched in the O-6 PUFA linoleic acid largely seem protective against coronary artery disease [<xref rid="R37" ref-type="bibr">37</xref>]. Nonetheless, several of the associations we identified between O-3 and O-6 intake and change in biomarkers persisted after adjusting for CVRF score, suggesting the nutrients might be associated with the AD-related pathological markers through pathways independent of vascular risk.</p><p id="P40">There are several studies linking intake of O-3 PUFAs with a lesser burden of amyloid pathology. One study showed that higher intake of O-3, vitamin B12 and vitamin D was associated with lower positron emission tomography (PET) amyloid burden in cognitively normal participants [<xref rid="R17" ref-type="bibr">17</xref>]. Another study reported higher O-3 intake was associated with lower level of cerebrospinal fluid (CSF) AD biomarkers in participants with mild AD, although inconsistent results on O-3 and CSF biomarkers also exist [<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>]. These suggest that higher O-3 intake may protect against amyloid pathological changes preceding and in early AD. We found that PUFAs were not associated with P-tau181 at baseline in the cross-sectional analysis but predicted less increase in phospho-tau longitudinally. One possible explanation of this is that, at baseline, the tau pathology might still be minimal in the study population, making it difficult to detect significant associations. In contrast, the change over many years of follow-up may better capture individual differences in tau dynamics. An alternative explanation is that cross-sectional P-tau levels are likely influenced by various individual factors such as age, metabolism, genetic predisposition, and comorbidities. In comparison, longitudinal changes in P-tau reflect within-individual trajectories and may be less affected by these external sources of variability.</p><p id="P41">There are few other observational studies on the influence of fatty acids on blood-based AD biomarkers, with varying results. In a cross-sectional study in our cohort, individuals with higher O-3 consumption had reduced plasma A<italic toggle="yes">&#x003b2;</italic>42 [<xref rid="R14" ref-type="bibr">14</xref>]. A multidomain interventional study including an O-3 supplement improved composite cognitive scores in non-demented individuals with low plasma A<italic toggle="yes">&#x003b2;</italic>42/40 ratio indicating risk of AD [<xref rid="R16" ref-type="bibr">16</xref>]. In a randomized controlled trial, treatment with a nutritional supplement containing EPA and DHA O-3 fatty acids did not affect P-tau181 or GFAP levels after 1 year compared to placebo [<xref rid="R15" ref-type="bibr">15</xref>].</p><p id="P42">Biological mechanisms that might be responsible for the association between O-3 and AD biomarkers are unclear. PUFAs are critical components of neuronal membranes, contributing to membrane fluidity and proper functioning of membrane-bound ion channels [<xref rid="R38" ref-type="bibr">38</xref>]. However, membrane PUFAs are also highly susceptible to lipid peroxidation due to their double bonds. Peroxidized PUFAs can initiate ferroptotic cell death by iron dependent enzymes [<xref rid="R39" ref-type="bibr">39</xref>], which leads to release of pro-inflammatory signals and activates microglia and astrocytes, contributing to AD. In a study of hypertensive older adults, oxidized products of O-3 and O-6 were associated with increased white matter hyperintensity and poorer executive function [<xref rid="R40" ref-type="bibr">40</xref>]. However, adequate levels of O-3 PUFAs have been shown to reduce oxidative stress by several mechanisms. They support synthesis of glutathione, which detoxifies lipid peroxides, and they improve expression of antioxidant enzymes, like glutathione peroxidase 4 [<xref rid="R39" ref-type="bibr">39</xref>]. Lastly, they promote the production of specialized pro-resolving mediators, such as resolvins and protectins, which help counteract peroxidation damage [<xref rid="R41" ref-type="bibr">41</xref>]. Overall, O-3 PUFAs may exert neuroprotective effects at least partly by reducing inflammation and oxidative stress.</p><p id="P43">Our study has several limitations. Dietary intake, which we assessed once at the initial visit, may have changed over time. However, we previously showed that dietary habits appear stable over time within individuals [<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R28" ref-type="bibr">28</xref>]. Misclassification of dietary data may be present, as the standard SFFQ used in our study might not fully capture all foods consumed by our multi-ethnic, elderly population, particularly the culturally specific or traditional foods. Given the observational nature of our study, we cannot make definite conclusions about whether intake of these key nutrients caused a lesser progression in biomarkers. It is possible that there was residual confounding of demographic and social factors with nutrient intake and the progression of AD pathophysiology. In addition, many individuals were missing PCA scores and/or CVRF score.</p><p id="P44">Plasma biomarkers, minimally invasive way to monitor AD-related brain changes, may provide valuable insight into the influence of diet on progression of AD pathophysiology before the onset of cognitive symptoms. This study suggests that individuals with calculated high tertiles of O-3 and O-6 PUFAs from food have lesser progression of AD biomarkers over time compared to those with low intakes. It also suggests that this protective association may occur separately from the effects of nutrition on cardiovascular risk. More studies are needed to understand this association, and to identify whether there might be individuals that could benefit from increased O-3 and O-6 intake, in the broad strategy to impact AD.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>supp</label><media xlink:href="NIHMS2073911-supplement-supp.docx" id="d67e1005" position="anchor"/></supplementary-material></sec></body><back><ack id="S25"><title>Funding</title><p id="P45">Data collection and sharing for this project was supported by the Washington Heights-Inwood Columbia Aging Project (WHICAP, R01 AG072474, RF1 AG066107, R01 AG059013, R01 AG061008) funded by the National Institute on Aging (NIA) and by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873.</p></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P46">Declaration of compting interest</p><p id="P47">The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</p><p id="P48">Dr. Brickman reports grants from NIH, during the conduct of the study; personal fees from Cedara, personal fees from Cogstate, personal fees from Cognito Therapeutics, personal fees from Cognition Therapeutics, personal fees from IQVIA, personal fees from International Neuropsychological Society, other from University of Illinois, Urbana-Champaign, other from Section editor, Alzheimer&#x02019;s &#x00026; Dementia, outside the submitted work; In addition, Dr. Brickman has a patent US Patent # 9,867,566 issued, and a patent US Patent# 20,230,298,170 pending.</p><p id="P49">Dr. Dage reports personal fees and other from Genotix Biotechnologies Inc, personal fees and other from AlzPath Inc, personal fees and other from Monument Biosciences, personal fees from Gates Ventures, personal fees from Karuna Therapeutics, personal fees from Cognito, personal fees and other from AbbVie, personal fees and other from Eisai, personal fees and other from Prevail Therapeutics, personal fees from Dolby Ventures, personal fees from Alzheimer&#x02019;s disease drug discovery fund, personal fees, non-financial support and other from Eli Lilly and Company, personal fees from Lab Corp, outside the submitted work; In addition, Dr. Dage has a patent COMPOUNDS AND METHODS TARGETING HUMAN TAU pending, and a patent Prevention of axonal damage using antibody binding to amyloid beta 1&#x02013;42 pending.</p><p id="P50">Dr. Manly reports grants from NINNIH P30 AG059303 ROl AG054070</p><p id="P51">NINDS/NIH UOl NS041588; NINNIH T35 AG044303 UOl AG009740, outside the submitted work;.</p><p id="P52">Dr. Honig reports grants and personal fees from Eisai, personal fees from Biogen, grants from Cognition, grants from EIP Pharma, grants from Acumen, grants from BMS, personal fees from New Amsterdam, personal fees from Prevail/ Lilly, grants from Ferrer, grants from Vaccinex, personal fees from Genentech/Roche, personal fees from Vigil, grants from Transposon, grants from GSK, grants from UCB, personal fees from Medscape, outside the submitted work;.</p><p id="P53">All other authors have nothing to disclose.</p></fn><fn id="FN3"><p id="P54">Declaration of generative AI and AI-assisted technologies in the writing process</p><p id="P55">We have not used any type of AI or its proportion in the writing process.</p></fn><fn id="FN4"><p id="P56">CRediT authorship contribution statement</p><p id="P57"><bold>Serena S. Hoost:</bold> Writing &#x02013; original draft, Formal analysis, Conceptualization. <bold>Lawrence S. Honig:</bold> Writing &#x02013; review &#x00026; editing, Validation, Methodology, Investigation. <bold>Min Suk Kang:</bold> Writing &#x02013; review &#x00026; editing, Investigation. <bold>Aanya Bahl:</bold> Writing &#x02013; review &#x00026; editing. <bold>Annie J. Lee:</bold> Writing &#x02013; review &#x00026; editing. <bold>Danurys Sanchez:</bold> Writing &#x02013; review &#x00026; editing, Investigation, Data curation. <bold>Dolly Reyes-Dumeyer:</bold> Writing &#x02013; review &#x00026; editing, Investigation, Data curation. <bold>Rafael A. Lantigua:</bold> Writing &#x02013; review &#x00026; editing, Investigation. <bold>Jeffrey L. Dage:</bold> Writing &#x02013; review &#x00026; editing, Methodology. <bold>Adam M. Brickman:</bold> Writing &#x02013; review &#x00026; editing, Methodology, Investigation. <bold>Jennifer J. Manly:</bold> Writing &#x02013; review &#x00026; editing, Methodology, Investigation. <bold>Richard Mayeux:</bold> Writing &#x02013; review &#x00026; editing, Supervision, Methodology, Investigation, Funding acquisition, Conceptualization. <bold>Yian Gu:</bold> Writing &#x02013; review &#x00026; editing, Supervision, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.</p></fn><fn id="FN5"><p id="P58">Supplementary materials</p><p id="P59">Supplementary material associated with this article can be found, in the online version, at doi:<ext-link xlink:href="10.1016/j.tjpad.2025.100117" ext-link-type="doi">10.1016/j.tjpad.2025.100117</ext-link>.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><name><surname>Scarmeas</surname><given-names>N</given-names></name>, <name><surname>Anastasiou</surname><given-names>CA</given-names></name>, <name><surname>Yannakoulia</surname><given-names>M</given-names></name>. <article-title>Nutrition and prevention of cognitive impairment</article-title>. <source>Lancet Neurol</source>
<year>2018</year>;<volume>17</volume>(<issue>11</issue>):<fpage>1006</fpage>&#x02013;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(18)30338-7</pub-id>.<pub-id pub-id-type="pmid">30244829</pub-id>
</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><name><surname>Bazinet</surname><given-names>RP</given-names></name>, <name><surname>Lay&#x000e9;</surname><given-names>S</given-names></name>. <article-title>Polyunsaturated fatty acids and their metabolites in brain function and disease</article-title>. <source>Nat Rev Neurosci</source>
<year>2014</year>;<volume>15</volume>(<issue>12</issue>):<fpage>771</fpage>&#x02013;<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrn3820</pub-id>.<pub-id pub-id-type="pmid">25387473</pub-id>
</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><name><surname>Glaser</surname><given-names>C</given-names></name>, <name><surname>Lattka</surname><given-names>E</given-names></name>, <name><surname>Rzehak</surname><given-names>P</given-names></name>, <name><surname>Steer</surname><given-names>C</given-names></name>, <name><surname>Koletzko</surname><given-names>B</given-names></name>. <article-title>Genetic variation in polyunsaturated fatty acid metabolism and its potential relevance for human development and health</article-title>. <source>Matern Child Nutr</source>
<year>2011</year>;<volume>7</volume>(<issue>Suppl 2</issue>):<fpage>27</fpage>&#x02013;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1740-8709.2011.00319.x</pub-id>.</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><name><surname>Rom&#x000e1;n</surname><given-names>GC</given-names></name>, <name><surname>Jackson</surname><given-names>RE</given-names></name>, <name><surname>Gadhia</surname><given-names>R</given-names></name>, <name><surname>Rom&#x000e1;n</surname><given-names>AN</given-names></name>, <name><surname>Reis</surname><given-names>J</given-names></name>. <article-title>Mediterranean diet: the role of long-chain <italic toggle="yes">&#x003c9;</italic>-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins in prevention of stroke, age-related cognitive decline, and Alzheimer disease</article-title>. <source>Rev Neurol (Paris)</source>
<year>2019</year>;<volume>175</volume>(<issue>10</issue>):<fpage>724</fpage>&#x02013;<lpage>41</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurol.2019.08.005</pub-id>.<pub-id pub-id-type="pmid">31521398</pub-id>
</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>BZ</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Dong</surname><given-names>CW</given-names></name>, <name><surname>Tan</surname><given-names>CC</given-names></name>, <name><surname>Xu</surname><given-names>W</given-names></name>. <article-title>The relationship of omega-3 fatty acids with dementia and cognitive decline: evidence from prospective cohort studies of supplementation, dietary intake, and blood markers</article-title>. <source>Am. J. Clin. Nutr</source>. <year>2023</year>;<volume>117</volume>(<issue>6</issue>):<fpage>1096</fpage>&#x02013;<lpage>109</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajcnut.2023.04.001</pub-id>.<pub-id pub-id-type="pmid">37028557</pub-id>
</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><name><surname>Kosti</surname><given-names>RI</given-names></name>, <name><surname>Kasdagli</surname><given-names>MI</given-names></name>, <name><surname>Kyrozis</surname><given-names>A</given-names></name>, <etal/>
<article-title>Fish intake, n-3 fatty acid body status, and risk of cognitive decline: a systematic review and a dose-response meta-analysis of observational and experimental studies</article-title>. <source>Nutr Rev</source>
<year>2022</year>;<volume>80</volume>(<issue>6</issue>):<fpage>1445</fpage>&#x02013;<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nutrit/nuab078</pub-id>.<pub-id pub-id-type="pmid">34605891</pub-id>
</mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><name><surname>Gustafson</surname><given-names>DR</given-names></name>, <name><surname>B&#x000e4;ckman</surname><given-names>K</given-names></name>, <name><surname>Scarmeas</surname><given-names>N</given-names></name>, <etal/>
<article-title>Dietary fatty acids and risk of Alzheimer&#x02019;s disease and related dementias: observations from the Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP)</article-title>. <source>Alzheimers Dement</source>
<year>2020</year>;<volume>16</volume>(<issue>12</issue>):<fpage>1638</fpage>&#x02013;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12154</pub-id>.<pub-id pub-id-type="pmid">32715635</pub-id>
</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><name><surname>de Oliveira Otto</surname><given-names>MC</given-names></name>, <name><surname>Wu</surname><given-names>JHY</given-names></name>, <name><surname>Thacker</surname><given-names>EL</given-names></name>, <etal/>
<article-title>Circulating omega-3 and omega-6 fatty acids, cognitive decline, and dementia in older adults</article-title>. <source>J Alzheimer&#x02019;s Dis</source>
<year>2023</year>;<volume>95</volume>(<issue>3</issue>):<fpage>965</fpage>&#x02013;<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-230083</pub-id>.<pub-id pub-id-type="pmid">37638432</pub-id>
</mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Yen</surname><given-names>D</given-names></name>, <name><surname>Hendrix</surname><given-names>RD</given-names></name>, <etal/>
<article-title>Timing of biomarker changes in sporadic Alzheimer&#x02019;s disease in estimated years from symptom onset</article-title>. <source>Ann Neurol</source>
<year>2024</year>;<volume>95</volume>(<issue>5</issue>):<fpage>951</fpage>&#x02013;<lpage>65</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.26891</pub-id>.<pub-id pub-id-type="pmid">38400792</pub-id>
</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><name><surname>Jia</surname><given-names>J</given-names></name>, <name><surname>Ning</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>M</given-names></name>, <etal/>
<article-title>Biomarker changes during 20 years preceding Alzheimer&#x02019;s disease</article-title>. <source>New England Journal of Medicine</source>
<year>2024</year>;<volume>390</volume>(<issue>8</issue>):<fpage>712</fpage>&#x02013;<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2310168</pub-id>.<pub-id pub-id-type="pmid">38381674</pub-id>
</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><name><surname>Villemagne</surname><given-names>VL</given-names></name>, <name><surname>Burnham</surname><given-names>S</given-names></name>, <name><surname>Bourgeat</surname><given-names>P</given-names></name>, <etal/>
<article-title>Amyloid <italic toggle="yes">&#x003b2;</italic> deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x02019;s disease: a prospective cohort study</article-title>. <source>Lancet Neurol</source>
<year>2013</year>;<volume>12</volume>(<issue>4</issue>):<fpage>357</fpage>&#x02013;<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422</pub-id>(13)70044&#x02013;9.<pub-id pub-id-type="pmid">23477989</pub-id>
</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><name><surname>Gu</surname><given-names>Y</given-names></name>, <name><surname>Honig</surname><given-names>LS</given-names></name>, <name><surname>Kang</surname><given-names>MS</given-names></name>, <etal/>
<article-title>Risk of Alzheimer&#x02019;s disease is associated with longitudinal changes in plasma biomarkers in the multi-ethnic Washington Heights&#x02013;Hamilton Heights&#x02013;Inwood Columbia Aging Project (WHICAP) cohort</article-title>. <source>Alzheimers Dement</source>
<year>2024</year>;<volume>20</volume>(<issue>3</issue>):<fpage>1988</fpage>&#x02013;<lpage>99</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13652</pub-id>.<pub-id pub-id-type="pmid">38183363</pub-id>
</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><name><surname>Pereira</surname><given-names>JB</given-names></name>, <name><surname>Janelidze</surname><given-names>S</given-names></name>, <name><surname>Stomrud</surname><given-names>E</given-names></name>, <etal/>
<article-title>Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects</article-title>. <source>Brain</source>
<year>2021</year>;<volume>144</volume>(<issue>9</issue>):<fpage>2826</fpage>&#x02013;<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awab163</pub-id>.<pub-id pub-id-type="pmid">34077494</pub-id>
</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><name><surname>Gu</surname><given-names>Y</given-names></name>, <name><surname>Schupf</surname><given-names>N</given-names></name>, <name><surname>Cosentino</surname><given-names>SA</given-names></name>, <name><surname>Luchsinger</surname><given-names>JA</given-names></name>, <name><surname>Scarmeas</surname><given-names>N</given-names></name>. <article-title>Nutrient intake and plasma <italic toggle="yes">&#x003b2;</italic>-amyloid</article-title>. <source>Neurology</source>
<year>2012</year>;<volume>78</volume>(<issue>23</issue>):<fpage>1832</fpage>&#x02013;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0b013e318258f7c2</pub-id>.<pub-id pub-id-type="pmid">22551728</pub-id>
</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><name><surname>Giudici</surname><given-names>KV</given-names></name>, <name><surname>de Souto</surname><given-names>Barreto P</given-names></name>, <name><surname>Guyonnet</surname><given-names>S</given-names></name>, <etal/>
<article-title>Effect of a 1-year nutritional blend supplementation on plasma p-tau181 and GFAP levels among community-dwelling older adults: a secondary analysis of the Nolan trial</article-title>. <source>JAR Life</source>
<year>2023</year>;<volume>12</volume>:<fpage>25</fpage>&#x02013;<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.14283/jarlife.2023.7</pub-id>.<pub-id pub-id-type="pmid">37351539</pub-id>
</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><name><surname>Delrieu</surname><given-names>J</given-names></name>, <name><surname>Vellas</surname><given-names>B</given-names></name>, <name><surname>Guyonnet</surname><given-names>S</given-names></name>, <etal/>
<article-title>Cognitive impact of multidomain intervention and omega 3 according to blood A<italic toggle="yes">&#x003b2;</italic>42/40 ratio: a subgroup analysis from the randomized MAPT trial</article-title>. <source>Alzheimer&#x02019;s Res Therapy</source>
<year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>183</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-023-01325-3</pub-id>.</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><name><surname>Mosconi</surname><given-names>L</given-names></name>, <name><surname>Murray</surname><given-names>J</given-names></name>, <name><surname>Davies</surname><given-names>M</given-names></name>, <etal/>
<article-title>Nutrient intake and brain biomarkers of Alzheimer&#x02019;s disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study</article-title>. <source>BMJ Open</source>
<year>2014</year>;<volume>4</volume>(<issue>6</issue>):<fpage>e004850</fpage>&#x02013;<lpage>e004850</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2014-004850</pub-id>.</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><name><surname>Freund-Levi</surname><given-names>Y</given-names></name>, <name><surname>Hjorth</surname><given-names>E</given-names></name>, <name><surname>Lindberg</surname><given-names>C</given-names></name>, <etal/>
<article-title>Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer&#x02019;s Disease: the OmegAD study</article-title>. <source>DEM</source>
<year>2009</year>;<volume>27</volume>(<issue>5</issue>):<fpage>481</fpage>&#x02013;<lpage>90</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000218081</pub-id>.</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><name><surname>Freund Levi</surname><given-names>Y</given-names></name>, <name><surname>Vedin</surname><given-names>I</given-names></name>, <name><surname>Cederholm</surname><given-names>T</given-names></name>, <etal/>
<article-title>Transfer of omega-3 fatty acids across the blood&#x02013;brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer&#x02019;s disease: the OmegAD study</article-title>. <source>J. Intern. Med</source>. <year>2014</year>;<volume>275</volume>(<issue>4</issue>):<fpage>428</fpage>&#x02013;<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.1111/joim.12166</pub-id>.<pub-id pub-id-type="pmid">24410954</pub-id>
</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><name><surname>Gu</surname><given-names>Y</given-names></name>, <name><surname>Honig</surname><given-names>LS</given-names></name>, <name><surname>Kang</surname><given-names>MS</given-names></name>, <etal/>
<article-title>Risk of Alzheimer&#x02019;s disease is associated with longitudinal changes in plasma biomarkers in the multiethnic Washington Heights</article-title>. <source>Inwood Columbia Aging Project Cohort</source>
<volume>2023</volume>:<fpage>23293967</fpage> Published online August 16, 2023.08.11. doi:<pub-id pub-id-type="doi">10.1101/2023.08.11.23293967</pub-id>.</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><name><surname>Ogino</surname><given-names>E</given-names></name>, <name><surname>Manly</surname><given-names>JJ</given-names></name>, <name><surname>Schupf</surname><given-names>N</given-names></name>, <name><surname>Mayeux</surname><given-names>R</given-names></name>, <name><surname>Gu</surname><given-names>Y</given-names></name>. <article-title>Current and past leisure time physical activity in relation to risk of Alzheimer&#x02019;s disease in older adults</article-title>. <source>Alzheimers Dement</source>
<year>2019</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1603</fpage>&#x02013;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2019.07.013</pub-id>.<pub-id pub-id-type="pmid">31587996</pub-id>
</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="book"><collab>Bureau USC</collab>. <source>Census of Population and HousingSummary population and housing characteristics</source>. <publisher-name>Bureau of the Census</publisher-name>; <year>2001</year>.</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><name><surname>McKhann</surname><given-names>GM</given-names></name>, <name><surname>Knopman</surname><given-names>DS</given-names></name>, <name><surname>Chertkow</surname><given-names>H</given-names></name>, <etal/>
<article-title>The diagnosis of dementia due to Alzheimer&#x02019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x02019;s Association workgroups on diagnostic guidelines for Alzheimer&#x02019;s disease</article-title>. <source>Alzheimers Dement</source>
<year>2011</year>;<volume>7</volume>(<issue>3</issue>):<fpage>263</fpage>&#x02013;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id>.<pub-id pub-id-type="pmid">21514250</pub-id>
</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>W</given-names></name>, <name><surname>Mitchell</surname><given-names>P</given-names></name>, <name><surname>Reay</surname><given-names>EM</given-names></name>, <name><surname>Webb</surname><given-names>K</given-names></name>, <name><surname>Harvey</surname><given-names>PWJ</given-names></name>. <article-title>Validity and reproducibility of a self-administered food frequency questionnaire in older people</article-title>. <source>Aust N Z J Public Health</source>
<year>1998</year>;<volume>22</volume>(<issue>4</issue>):<fpage>456</fpage>&#x02013;<lpage>63</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1467-842X.1998.tb01414.x</pub-id>.<pub-id pub-id-type="pmid">9659773</pub-id>
</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><name><surname>Gu</surname><given-names>Y</given-names></name>, <name><surname>Nieves</surname><given-names>JW</given-names></name>, <name><surname>Stern</surname><given-names>Y</given-names></name>, <name><surname>Luchsinger</surname><given-names>JA</given-names></name>, <name><surname>Scarmeas</surname><given-names>N</given-names></name>. <article-title>Food combination and Alzheimer disease risk</article-title>. <source>Arch Neurol</source>
<year>2010</year>;<volume>67</volume>(<issue>6</issue>):<fpage>699</fpage>&#x02013;<lpage>706</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneurol.2010.84</pub-id>.<pub-id pub-id-type="pmid">20385883</pub-id>
</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="book"><name><surname>Willett</surname><given-names>W</given-names></name>
<source>Nutritional epidemiology</source>. <edition>2nd</edition> ed. <publisher-name>Oxford University Press</publisher-name>; <year>1998</year>.</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="webpage"><collab>Department of Agriculture US</collab>. <source>Dietary Guidelines for Americans, 2020&#x02013;2025</source>
<year>2020</year>. Accessed <date-in-citation>January 20, 2025</date-in-citation>
<ext-link xlink:href="https://www.dietaryguidelines.gov/" ext-link-type="uri">https://www.dietaryguidelines.gov/</ext-link>.</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><name><surname>Scarmeas</surname><given-names>N</given-names></name>, <name><surname>Stern</surname><given-names>Y</given-names></name>, <name><surname>Tang</surname><given-names>MX</given-names></name>, <name><surname>Mayeux</surname><given-names>R</given-names></name>, <name><surname>Luchsinger</surname><given-names>JA</given-names></name>. <article-title>Mediterranean diet and risk for Alzheimer&#x02019;s disease</article-title>. <source>Ann Neurol</source>
<year>2006</year>;<volume>59</volume>(<issue>6</issue>):<fpage>912</fpage>&#x02013;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.20854</pub-id>.<pub-id pub-id-type="pmid">16622828</pub-id>
</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>AJ</given-names></name>, <name><surname>Raghavan</surname><given-names>NS</given-names></name>, <name><surname>Bhattarai</surname><given-names>P</given-names></name>, <etal/>
<article-title>FMNL2 regulates gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol</source>
<year>2022</year>;<volume>144</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02013;<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00401-022-02431-6</pub-id>.<pub-id pub-id-type="pmid">35608697</pub-id>
</mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>AJ</given-names></name>, <name><surname>Sanchez</surname><given-names>D</given-names></name>, <name><surname>Reyes-Dumeyer</surname><given-names>D</given-names></name>, <etal/>
<source>Reliability and validity of self-reported vascular risk factors in a Multi-Ethnic community based study of aging and dementia</source>. Published online April 17, 2023:2023.04.12.23288492. doi:<pub-id pub-id-type="doi">10.1101/2023.04.12.23288492</pub-id>.</mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><name><surname>Charlson</surname><given-names>ME</given-names></name>, <name><surname>Carrozzino</surname><given-names>D</given-names></name>, <name><surname>Guidi</surname><given-names>J</given-names></name>, <name><surname>Patierno</surname><given-names>C</given-names></name>. <article-title>Charlson Comorbidity Index: a Critical Review of Clinimetric properties</article-title>. <source>Psychother Psychosom</source>
<year>2022</year>;<volume>91</volume>(<issue>1</issue>):<fpage>8</fpage>&#x02013;<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000521288</pub-id>.<pub-id pub-id-type="pmid">34991091</pub-id>
</mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><name><surname>Ramanan</surname><given-names>VK</given-names></name>, <name><surname>Graff-Radford</surname><given-names>J</given-names></name>, <name><surname>Syrjanen</surname><given-names>J</given-names></name>, <etal/>
<article-title>Association of plasma biomarkers of Alzheimer disease with cognition and medical comorbidities in a biracial cohort</article-title>. <source>Neurology</source>
<year>2023</year>;<volume>101</volume>(<issue>14</issue>):<fpage>e1402</fpage>&#x02013;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000207675</pub-id>.<pub-id pub-id-type="pmid">37580163</pub-id>
</mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><name><surname>Merten</surname><given-names>N</given-names></name>, <name><surname>Pinto</surname><given-names>AA</given-names></name>, <name><surname>Paulsen</surname><given-names>AJ</given-names></name>, <etal/>
<article-title>Associations of midlife lifestyle and health factors with long-term changes in blood-based biomarkers of Alzheimer&#x02019;s disease and neurodegeneration</article-title>. <source>J Alzheimer&#x02019;s Dis</source>
<year>2023</year>;<volume>94</volume>(<issue>4</issue>):<fpage>1381</fpage>&#x02013;<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-221287</pub-id>.<pub-id pub-id-type="pmid">37393497</pub-id>
</mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><name><surname>Mielke</surname><given-names>MM</given-names></name>, <name><surname>Dage</surname><given-names>JL</given-names></name>, <name><surname>Frank</surname><given-names>RD</given-names></name>, <etal/>
<article-title>Performance of plasma phosphorylated tau 181 and 217 in the community</article-title>. <source>Nat Med</source>. <year>2022</year> Published online May 26. doi:<pub-id pub-id-type="doi">10.1038/s41591-022-01822-2</pub-id>.</mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><name><surname>Mielke</surname><given-names>MM</given-names></name>, <name><surname>Frank</surname><given-names>RD</given-names></name>, <name><surname>Dage</surname><given-names>JL</given-names></name>, <etal/>
<article-title>Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes</article-title>. <source>JAMA Neurol</source>
<year>2021</year>;<volume>78</volume>(<issue>9</issue>):<fpage>1108</fpage>&#x02013;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2021.2293</pub-id>.<pub-id pub-id-type="pmid">34309632</pub-id>
</mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><name><surname>Edwards</surname><given-names>NC</given-names></name>, <name><surname>Lao</surname><given-names>PJ</given-names></name>, <name><surname>Alshikho</surname><given-names>MJ</given-names></name>, <etal/>
<source>Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome</source>. Published online November 30, 2023:2023.11.28.23298693. doi:<pub-id pub-id-type="doi">10.1101/2023.11.28.23298693</pub-id>.</mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><name><surname>Schulze</surname><given-names>MB</given-names></name>, <name><surname>Minihane</surname><given-names>AM</given-names></name>, <name><surname>Saleh</surname><given-names>RNM</given-names></name>, <name><surname>Ris&#x000e9;rus</surname><given-names>U</given-names></name>. <article-title>Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases</article-title>. <source>Lancet Diabetes Endocrinol</source>
<year>2020</year>;<volume>8</volume>(<issue>11</issue>):<fpage>915</fpage>&#x02013;<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2213-8587(20)30148-0</pub-id>.<pub-id pub-id-type="pmid">32949497</pub-id>
</mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><name><surname>Janssen</surname><given-names>CIF</given-names></name>, <name><surname>Kiliaan</surname><given-names>AJ</given-names></name>. <article-title>Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration</article-title>. <source>Prog. Lipid Res</source>. <year>2014</year>;<volume>53</volume>:<fpage>1</fpage>&#x02013;<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.plipres.2013.10.002</pub-id>.<pub-id pub-id-type="pmid">24334113</pub-id>
</mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>WS</given-names></name>, <name><surname>Kim</surname><given-names>KJ</given-names></name>, <name><surname>Gaschler</surname><given-names>MM</given-names></name>, <name><surname>Patel</surname><given-names>M</given-names></name>, <name><surname>Shchepinov</surname><given-names>MS</given-names></name>, <name><surname>Stockwell</surname><given-names>BR</given-names></name>. <article-title>Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2016</year>;<volume>113</volume>(<issue>34</issue>):<fpage>E4966</fpage>&#x02013;<lpage>75</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1603244113</pub-id>.<pub-id pub-id-type="pmid">27506793</pub-id>
</mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><name><surname>Shinto</surname><given-names>L</given-names></name>, <name><surname>Lahna</surname><given-names>D</given-names></name>, <name><surname>Murchison</surname><given-names>CF</given-names></name>, <etal/>
<article-title>Oxidized products of omega-6 and omega-3 long chain fatty acids are associated with increased white matter hyperintensity and poorer executive function performance in a cohort of cognitively normal hypertensive older adults</article-title>. <source>J Alzheimers Dis</source>
<year>2020</year>;<volume>74</volume>(<issue>1</issue>):<fpage>65</fpage>&#x02013;<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-191197</pub-id>.<pub-id pub-id-type="pmid">32176647</pub-id>
</mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><name><surname>Bazan</surname><given-names>NG</given-names></name>, <name><surname>Molina</surname><given-names>MF</given-names></name>, <name><surname>Gordon</surname><given-names>WC</given-names></name>. <article-title>Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer&#x02019;s, and other neurodegenerative diseases</article-title>. <source>Annu Rev Nutr</source>
<year>2011</year>;<volume>31</volume>:<fpage>321</fpage>&#x02013;<lpage>51</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.nutr.012809.104635</pub-id>.<pub-id pub-id-type="pmid">21756134</pub-id>
</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Fig. 1.</label><caption><p id="P60">Baseline biomarker levels by nutrient intake tertile. Abbreviations (units): O-3, omega-3: O-6, omega-6: PUFA, polyunsaturated fatty acid: MUFA, monounsaturated fatty acid: P-tau181, phosphorylated tau 181 level (pg/ml, log10-transformed): A<italic toggle="yes">&#x003b2;</italic>42/40, amyloid-beta 42/40 ratio (log10-transformed): GFAP, glial fibrillary acidic protein level (pg/ml, log10-transformed): NfL, neurofilament light chain level (pg/ml, log10-transformed): PCA1, first principal component (derived from the latter four biomarkers): PCA2, second principal component. Generalized linear models were used to evaluate the association of nutrient intake (high and middle compared to low tertiles) with baseline biomarker level. Missing values excluded. <italic toggle="yes">N</italic> = 593 for A<italic toggle="yes">&#x003b2;</italic>42/40, <italic toggle="yes">N</italic> = 598 for GFAP and NfL, <italic toggle="yes">N</italic> = 597 for P-tau181, <italic toggle="yes">N</italic> = 593 for P-tau181/ A<italic toggle="yes">&#x003b2;</italic>42, <italic toggle="yes">N</italic> = 520 for PCAs. The model was adjusted for total calorie intake, age, sex, ethnicity, education, and storage time. No comparisons were statistically significant after correction for 21 comparisons using the False Discovery Rate method.</p></caption><graphic xlink:href="nihms-2073911-f0001" position="float"/></fig><fig position="float" id="F2"><label>Fig. 2.</label><caption><p id="P61">Longitudinal biomarker levels by nutrient intake tertile.</p><p id="P62">Abbreviations (units): O-3, omega-3: O-6, omega-6: PUFA, polyunsaturated fatty acid: MUFA, monounsaturated fatty acid: P-tau181, phosphorylated tau 181 level (pg/ml, log10-transformed): A<italic toggle="yes">&#x003b2;</italic>42/40, amyloid-beta 42/40 ratio (log10-transformed): GFAP, glial fibrillary acidic protein level (pg/ml, log10-transformed): NfL, neurofilament light chain level (pg/ml, log10-transformed). Generalized estimating equations (GEE) were used to evaluate the association of nutrient intake (high and middle compared to low tertiles) with change in biomarker level over time (in visits). The results of model 2, adjusted for total energy intake, age, sex, ethnicity, education and storage time, are shown (<italic toggle="yes">N</italic> = 598). <sup>&#x02217;</sup> False discovery rate (FDR) adjusted P-values from trend analysis &#x0003c;0.05, corresponding to filled squares in the graph. Open circles denote non-significant differences.</p></caption><graphic xlink:href="nihms-2073911-f0002" position="float"/></fig><fig position="float" id="F3"><label>Fig. 3.</label><caption><p id="P63">Longitudinal principal component scores by nutrient intake tertiles.</p><p id="P64">Abbreviations (units): O-3, omega-3: O-6, omega-6: PUFA, polyunsaturated fatty acid: MUFA, monounsaturated fatty acid: PCA1, first principal component (derived from the latter four biomarkers): PCA2, second principal component. Generalized estimating equations (GEE) were used to evaluate the association of nutrient intake (high and middle compared to low tertiles) with change in principal component score over time (in visits). The results of model 2, adjusted for total energy intake, age, sex, ethnicity, education and storage time, are shown (<italic toggle="yes">N</italic> = 598). <sup>&#x02217;</sup> False discovery rate (FDR) adjusted P-values from trend analysis &#x0003c;0.05, corresponding to filled squares in the graph. Open circles denote non-significant differences.</p></caption><graphic xlink:href="nihms-2073911-f0003" position="float"/></fig><table-wrap position="float" id="T1" orientation="landscape"><label>Table 1</label><caption><p id="P65">Summary of participants by O-3 PUFA intake tertile.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" valign="bottom" colspan="1">Characteristic<xref rid="TFN2" ref-type="table-fn">*</xref></th><th colspan="4" align="left" valign="bottom" rowspan="1">O-3 PUFA Intake Tertile<hr/></th><th rowspan="2" align="left" valign="bottom" colspan="1">p-value<xref rid="TFN2" ref-type="table-fn">*</xref></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">LOW <italic toggle="yes">N</italic> = 200<sup><xref rid="TFN3" ref-type="table-fn">&#x02020;</xref></sup></th><th align="left" valign="bottom" rowspan="1" colspan="1">MIDDLE <italic toggle="yes">N</italic> = 199<sup><xref rid="TFN3" ref-type="table-fn">&#x02020;</xref></sup></th><th align="left" valign="bottom" rowspan="1" colspan="1">HIGH <italic toggle="yes">N</italic> = 200<sup><xref rid="TFN3" ref-type="table-fn">&#x02020;</xref></sup></th><th align="left" valign="bottom" rowspan="1" colspan="1">Overall <italic toggle="yes">N</italic> = 599<sup><xref rid="TFN4" ref-type="table-fn">&#x02021;</xref></sup></th></tr><tr><th colspan="6" align="left" valign="top" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">O-3 PUFA, mg/d</td><td align="left" valign="top" rowspan="1" colspan="1">86.4 (77.6)</td><td align="left" valign="top" rowspan="1" colspan="1">200 (162)</td><td align="left" valign="top" rowspan="1" colspan="1">463 (454)</td><td align="left" valign="top" rowspan="1" colspan="1">250 (323)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="left" valign="top" rowspan="1" colspan="1">74.5 (5.88)</td><td align="left" valign="top" rowspan="1" colspan="1">74.6 (6.08)</td><td align="left" valign="top" rowspan="1" colspan="1">72.3 (4.91)</td><td align="left" valign="top" rowspan="1" colspan="1">73.8 (5.74)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Women</td><td align="left" valign="top" rowspan="1" colspan="1">143 (72%)</td><td align="left" valign="top" rowspan="1" colspan="1">135 (68%)</td><td align="left" valign="top" rowspan="1" colspan="1">139 (70%)</td><td align="left" valign="top" rowspan="1" colspan="1">417 (70%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Men</td><td align="left" valign="top" rowspan="1" colspan="1">57 (29%)</td><td align="left" valign="top" rowspan="1" colspan="1">64 (32%)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (31%)</td><td align="left" valign="top" rowspan="1" colspan="1">182 (30%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ethnicity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.130</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-Hispanic White</td><td align="left" valign="top" rowspan="1" colspan="1">53 (27%)</td><td align="left" valign="top" rowspan="1" colspan="1">52 (26%)</td><td align="left" valign="top" rowspan="1" colspan="1">62 (31%)</td><td align="left" valign="top" rowspan="1" colspan="1">167 (28%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-Hispanic Black</td><td align="left" valign="top" rowspan="1" colspan="1">42 (21%)</td><td align="left" valign="top" rowspan="1" colspan="1">50 (25%)</td><td align="left" valign="top" rowspan="1" colspan="1">58 (29%)</td><td align="left" valign="top" rowspan="1" colspan="1">150 (25%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">105 (53%)</td><td align="left" valign="top" rowspan="1" colspan="1">97 (49%)</td><td align="left" valign="top" rowspan="1" colspan="1">80 (40%)</td><td align="left" valign="top" rowspan="1" colspan="1">282 (47%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Energy intake, kcal</td><td align="left" valign="top" rowspan="1" colspan="1">1.47 (0.46)</td><td align="left" valign="top" rowspan="1" colspan="1">1.28 (0.453)</td><td align="left" valign="top" rowspan="1" colspan="1">1.26 (0.397)</td><td align="left" valign="top" rowspan="1" colspan="1">1.34 (0.447)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Consumption of 2+ portions of fish, weekly</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.5%)</td><td align="left" valign="top" rowspan="1" colspan="1">80 (40%)</td><td align="left" valign="top" rowspan="1" colspan="1">200 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">281 (48%)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">O-6 PUFA, mg/d</td><td align="left" valign="top" rowspan="1" colspan="1">7880 (4020)</td><td align="left" valign="top" rowspan="1" colspan="1">6640 (3530)</td><td align="left" valign="top" rowspan="1" colspan="1">7420 (3860)</td><td align="left" valign="top" rowspan="1" colspan="1">7310 (3840)</td><td align="left" valign="top" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MUFA, mg/d</td><td align="left" valign="top" rowspan="1" colspan="1">15,600 (7050)</td><td align="left" valign="top" rowspan="1" colspan="1">13,100 (6420)</td><td align="left" valign="top" rowspan="1" colspan="1">13,800 (6440)</td><td align="left" valign="top" rowspan="1" colspan="1">14,200 (6710)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MeDi score</td><td align="left" valign="top" rowspan="1" colspan="1">3.8 (1.56)</td><td align="left" valign="top" rowspan="1" colspan="1">4.54 (1.73)</td><td align="left" valign="top" rowspan="1" colspan="1">5.14 (1.35)</td><td align="left" valign="top" rowspan="1" colspan="1">4.5 (1.64)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education, years</td><td align="left" valign="top" rowspan="1" colspan="1">10.3 (5.42)</td><td align="left" valign="top" rowspan="1" colspan="1">10.9 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">12.6 (5.19)</td><td align="left" valign="top" rowspan="1" colspan="1">11.3 (5.33)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APOE <italic toggle="yes">&#x003b5;</italic>4 allele<sup>&#x000a7;</sup></td><td align="left" valign="top" rowspan="1" colspan="1">50 (25%)</td><td align="left" valign="top" rowspan="1" colspan="1">54 (27%)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (24%)</td><td align="left" valign="top" rowspan="1" colspan="1">151 (25%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.718</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m^2)</td><td align="left" valign="top" rowspan="1" colspan="1">27.9 (4.36)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (4%)</td><td align="left" valign="top" rowspan="1" colspan="1">27.8 (4.63)</td><td align="left" valign="top" rowspan="1" colspan="1">27.5 (4.36)</td><td align="left" valign="top" rowspan="1" colspan="1">0.123</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" valign="top" rowspan="1" colspan="1">64 (32%)</td><td align="left" valign="top" rowspan="1" colspan="1">62 (31%)</td><td align="left" valign="top" rowspan="1" colspan="1">73 (37%)</td><td align="left" valign="top" rowspan="1" colspan="1">199 (33%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.476</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heart disease</td><td align="left" valign="top" rowspan="1" colspan="1">96 (48%)</td><td align="left" valign="top" rowspan="1" colspan="1">89 (45%)</td><td align="left" valign="top" rowspan="1" colspan="1">75 (38%)</td><td align="left" valign="top" rowspan="1" colspan="1">260 (43%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.095</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="left" valign="top" rowspan="1" colspan="1">173 (87%)</td><td align="left" valign="top" rowspan="1" colspan="1">162 (81%)</td><td align="left" valign="top" rowspan="1" colspan="1">168 (84%)</td><td align="left" valign="top" rowspan="1" colspan="1">503 (84%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.382</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Charlson Comorbidity Index</td><td align="left" valign="top" rowspan="1" colspan="1">2.21 (1.47)</td><td align="left" valign="top" rowspan="1" colspan="1">2.19 (1.48)</td><td align="left" valign="top" rowspan="1" colspan="1">2.18 (1.53)</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (1.49)</td><td align="left" valign="top" rowspan="1" colspan="1">0.984</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Incident dementia</td><td align="left" valign="top" rowspan="1" colspan="1">32 (16%)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (14%)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (10%)</td><td align="left" valign="top" rowspan="1" colspan="1">79 (13%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.204</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-tau181 level (pg/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">2.78 (2.53)</td><td align="left" valign="top" rowspan="1" colspan="1">2.44 (1.36)</td><td align="left" valign="top" rowspan="1" colspan="1">2.66 (2.15)</td><td align="left" valign="top" rowspan="1" colspan="1">2.63 (2.07)</td><td align="left" valign="top" rowspan="1" colspan="1">0.179</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GFAP level (pg/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">185 (97.8)</td><td align="left" valign="top" rowspan="1" colspan="1">163 (82.5)</td><td align="left" valign="top" rowspan="1" colspan="1">162 (121)</td><td align="left" valign="top" rowspan="1" colspan="1">170 (102)</td><td align="left" valign="top" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NfL level (pg/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">23.9 (13.2)</td><td align="left" valign="top" rowspan="1" colspan="1">20.9 (11.4)</td><td align="left" valign="top" rowspan="1" colspan="1">20.8 (11.4)</td><td align="left" valign="top" rowspan="1" colspan="1">21.8 (12.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.020</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-tau181/A<italic toggle="yes">&#x003b2;</italic>42 ratio</td><td align="left" valign="top" rowspan="1" colspan="1">0.443 (0.999)</td><td align="left" valign="top" rowspan="1" colspan="1">0.407 (1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.472 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.441 (1.34)</td><td align="left" valign="top" rowspan="1" colspan="1">0.893</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A<italic toggle="yes">&#x003b2;</italic>42/40 ratio</td><td align="left" valign="top" rowspan="1" colspan="1">0.0555 (0.0656)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0484 (0.0239)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0447 (0.0179)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0495 (0.0419)</td><td align="left" valign="top" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PCA1</td><td align="left" valign="top" rowspan="1" colspan="1">0.161 (1.11)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.0668 (0.868)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.157 (0.974)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.0249 (0.992)</td><td align="left" valign="top" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PCA2</td><td align="left" valign="top" rowspan="1" colspan="1">0.112 (1.23)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0336 (0.96)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.0855 (0.737)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0176 (0.992)</td><td align="left" valign="top" rowspan="1" colspan="1">0.146</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P66">Abbreviations (units): O-3, omega-3 (mg/day): O-6, omega-6 (mg/day): PUFA, polyunsaturated fatty acid (mg/day): MUFA, monounsaturated fatty acid (mg/day): APOE <italic toggle="yes">&#x003b5;</italic>4, apolipoprotein E epsilon 4 allele: MeDi, Mediterranean diet score: BMI, body mass index (kg/m^2): P-tau181, phosphorylated tau 181 (pg/ml): A<italic toggle="yes">&#x003b2;</italic>42/40, amyloid-beta 42/40 ratio: GFAP, glial fibrillary acidic protein (pg/ml): NfL, neurofilament light chain (pg/ml): PCA1, first principal component (derived from the latter four biomarkers): PCA2, second principal component.</p></fn><fn id="TFN2"><label>*</label><p id="P67">Missing values were excluded from analysis. Fish intake available for 591 individuals, education available for 598 individuals, APOE <italic toggle="yes">&#x003b5;</italic>4 available for 598 individuals, MeDi score available for 591 individuals, BMI available for 522 individuals, Charlson Comorbidity Index available for 597 individuals, P-tau181 available for 598 individuals, A<italic toggle="yes">&#x003b2;</italic>42/40 available for 594 individuals.</p></fn><fn id="TFN3"><label>&#x02020;</label><p id="P68">Mean (SD); n (%).</p></fn><fn id="TFN4"><label>&#x02021;</label><p id="P69">One-way analysis of means (not assuming equal variances); Pearson&#x02019;s Chi-squared test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="landscape"><label>Table 2</label><caption><p id="P70">Association of baseline nutrient intake tertile with longitudinal biomarker changes.</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" valign="middle" colspan="1">Intake</th><th rowspan="2" align="left" valign="middle" colspan="1">Biomarker</th><th colspan="2" align="left" valign="top" rowspan="1">Model 1<xref rid="TFN7" ref-type="table-fn">*</xref><hr/></th><th colspan="2" align="left" valign="top" rowspan="1">Model 2<sup><xref rid="TFN8" ref-type="table-fn">&#x02020;</xref></sup><hr/></th><th align="left" valign="top" rowspan="1" colspan="1">Trend<sup><xref rid="TFN9" ref-type="table-fn">&#x02021;</xref></sup></th><th colspan="2" align="left" valign="top" rowspan="1">Model 3<sup><xref rid="TFN10" ref-type="table-fn">&#x000a7;</xref></sup><hr/></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Estimate</th><th align="left" valign="top" rowspan="1" colspan="1">P</th><th align="left" valign="top" rowspan="1" colspan="1">Estimate</th><th align="left" valign="top" rowspan="1" colspan="1">P</th><th align="left" valign="top" rowspan="1" colspan="1">Corrected P</th><th align="left" valign="top" rowspan="1" colspan="1">Estimate</th><th align="left" valign="top" rowspan="1" colspan="1">P</th></tr><tr><th colspan="9" align="left" valign="top" rowspan="1">
<hr/>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>MUFA intake tertile</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">P-tau181</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.019</td><td align="left" valign="top" rowspan="1" colspan="1">0.159</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.019</td><td align="left" valign="top" rowspan="1" colspan="1">0.149</td><td align="left" valign="top" rowspan="1" colspan="1">0.315</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.026</td><td align="left" valign="top" rowspan="1" colspan="1">0.113</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.026</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.027</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.026</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.024</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.020</td><td align="left" valign="top" rowspan="1" colspan="1">0.157</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">A<italic toggle="yes">&#x003b2;</italic>42/40</td><td align="left" valign="top" rowspan="1" colspan="1">0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.397</td><td align="left" valign="top" rowspan="1" colspan="1">0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.387</td><td align="left" valign="top" rowspan="1" colspan="1">0.575</td><td align="left" valign="top" rowspan="1" colspan="1">0.013</td><td align="left" valign="top" rowspan="1" colspan="1">0.113</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.009</td><td align="left" valign="top" rowspan="1" colspan="1">0.240</td><td align="left" valign="top" rowspan="1" colspan="1">0.008</td><td align="left" valign="top" rowspan="1" colspan="1">0.281</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.017</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.039</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">P-tau181/A<italic toggle="yes">&#x003b2;</italic>42</td><td align="left" valign="top" rowspan="1" colspan="1">0.025</td><td align="left" valign="top" rowspan="1" colspan="1">0.146</td><td align="left" valign="top" rowspan="1" colspan="1">0.025</td><td align="left" valign="top" rowspan="1" colspan="1">0.143</td><td align="left" valign="top" rowspan="1" colspan="1">0.315</td><td align="left" valign="top" rowspan="1" colspan="1">0.035</td><td align="left" valign="top" rowspan="1" colspan="1">0.089</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.025</td><td align="left" valign="top" rowspan="1" colspan="1">0.160</td><td align="left" valign="top" rowspan="1" colspan="1">0.024</td><td align="left" valign="top" rowspan="1" colspan="1">0.172</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.040</td><td align="left" valign="top" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">GFAP</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.014</td><td align="left" valign="top" rowspan="1" colspan="1">0.144</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.014</td><td align="left" valign="top" rowspan="1" colspan="1">0.136</td><td align="left" valign="top" rowspan="1" colspan="1">0.315</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.016</td><td align="left" valign="top" rowspan="1" colspan="1">0.166</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.013</td><td align="left" valign="top" rowspan="1" colspan="1">0.161</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.013</td><td align="left" valign="top" rowspan="1" colspan="1">0.150</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.010</td><td align="left" valign="top" rowspan="1" colspan="1">0.376</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">NfL</td><td align="left" valign="top" rowspan="1" colspan="1">0.015</td><td align="left" valign="top" rowspan="1" colspan="1">0.160</td><td align="left" valign="top" rowspan="1" colspan="1">0.015</td><td align="left" valign="top" rowspan="1" colspan="1">0.172</td><td align="left" valign="top" rowspan="1" colspan="1">0.315</td><td align="left" valign="top" rowspan="1" colspan="1">0.012</td><td align="left" valign="top" rowspan="1" colspan="1">0.383</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.572</td><td align="left" valign="top" rowspan="1" colspan="1">0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.594</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.013</td><td align="left" valign="top" rowspan="1" colspan="1">0.287</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">PCA1</td><td align="left" valign="top" rowspan="1" colspan="1">0.022</td><td align="left" valign="top" rowspan="1" colspan="1">0.612</td><td align="left" valign="top" rowspan="1" colspan="1">0.023</td><td align="left" valign="top" rowspan="1" colspan="1">0.601</td><td align="left" valign="top" rowspan="1" colspan="1">0.666</td><td align="left" valign="top" rowspan="1" colspan="1">0.034</td><td align="left" valign="top" rowspan="1" colspan="1">0.534</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.016</td><td align="left" valign="top" rowspan="1" colspan="1">0.724</td><td align="left" valign="top" rowspan="1" colspan="1">0.013</td><td align="left" valign="top" rowspan="1" colspan="1">0.774</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.066</td><td align="left" valign="top" rowspan="1" colspan="1">0.219</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">PCA2</td><td align="left" valign="top" rowspan="1" colspan="1">0.016</td><td align="left" valign="top" rowspan="1" colspan="1">0.773</td><td align="left" valign="top" rowspan="1" colspan="1">0.016</td><td align="left" valign="top" rowspan="1" colspan="1">0.767</td><td align="left" valign="top" rowspan="1" colspan="1">0.771</td><td align="left" valign="top" rowspan="1" colspan="1">0.040</td><td align="left" valign="top" rowspan="1" colspan="1">0.541</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.022</td><td align="left" valign="top" rowspan="1" colspan="1">0.701</td><td align="left" valign="top" rowspan="1" colspan="1">0.016</td><td align="left" valign="top" rowspan="1" colspan="1">0.779</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.045</td><td align="left" valign="top" rowspan="1" colspan="1">0.483</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">
<bold>O-3 PUFA intake tertile</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">P-tau181</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.037</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.037</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.006</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.030</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.027</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.014</td><td align="left" valign="top" rowspan="1" colspan="1">0.308</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.014</td><td align="left" valign="top" rowspan="1" colspan="1">0.315</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.960</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">A<italic toggle="yes">&#x003b2;</italic>42/40</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.023</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.022</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.013</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.013</td><td align="left" valign="top" rowspan="1" colspan="1">0.097</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.010</td><td align="left" valign="top" rowspan="1" colspan="1">0.212</td><td align="left" valign="top" rowspan="1" colspan="1">0.010</td><td align="left" valign="top" rowspan="1" colspan="1">0.209</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.004</td><td align="left" valign="top" rowspan="1" colspan="1">0.631</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">P-tau181/A<italic toggle="yes">&#x003b2;</italic>42</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.025</td><td align="left" valign="top" rowspan="1" colspan="1">0.129</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.026</td><td align="left" valign="top" rowspan="1" colspan="1">0.119</td><td align="left" valign="top" rowspan="1" colspan="1">0.315</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.028</td><td align="left" valign="top" rowspan="1" colspan="1">0.163</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.015</td><td align="left" valign="top" rowspan="1" colspan="1">0.418</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.014</td><td align="left" valign="top" rowspan="1" colspan="1">0.444</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.010</td><td align="left" valign="top" rowspan="1" colspan="1">0.638</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">GFAP</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.538</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.007</td><td align="left" valign="top" rowspan="1" colspan="1">0.502</td><td align="left" valign="top" rowspan="1" colspan="1">0.586</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.003</td><td align="left" valign="top" rowspan="1" colspan="1">0.830</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.004</td><td align="left" valign="top" rowspan="1" colspan="1">0.700</td><td align="left" valign="top" rowspan="1" colspan="1">0.004</td><td align="left" valign="top" rowspan="1" colspan="1">0.683</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.621</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">NfL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.003</td><td align="left" valign="top" rowspan="1" colspan="1">0.775</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.003</td><td align="left" valign="top" rowspan="1" colspan="1">0.738</td><td align="left" valign="top" rowspan="1" colspan="1">0.771</td><td align="left" valign="top" rowspan="1" colspan="1">0.010</td><td align="left" valign="top" rowspan="1" colspan="1">0.425</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.008</td><td align="left" valign="top" rowspan="1" colspan="1">0.470</td><td align="left" valign="top" rowspan="1" colspan="1">0.009</td><td align="left" valign="top" rowspan="1" colspan="1">0.449</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.018</td><td align="left" valign="top" rowspan="1" colspan="1">0.180</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">PCA1</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.026</td><td align="left" valign="top" rowspan="1" colspan="1">0.573</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.031</td><td align="left" valign="top" rowspan="1" colspan="1">0.492</td><td align="left" valign="top" rowspan="1" colspan="1">0.586</td><td align="left" valign="top" rowspan="1" colspan="1">0.004</td><td align="left" valign="top" rowspan="1" colspan="1">0.942</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.005</td><td align="left" valign="top" rowspan="1" colspan="1">0.908</td><td align="left" valign="top" rowspan="1" colspan="1">0.007</td><td align="left" valign="top" rowspan="1" colspan="1">0.882</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.020</td><td align="left" valign="top" rowspan="1" colspan="1">0.726</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">PCA2</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.225</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.221</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.168</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.010</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.112</td><td align="left" valign="top" rowspan="1" colspan="1">0.064</td><td align="left" valign="top" rowspan="1" colspan="1">0.113</td><td align="left" valign="top" rowspan="1" colspan="1">0.060</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.065</td><td align="left" valign="top" rowspan="1" colspan="1">0.348</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">
<bold>O-6 PUFA intake tertile</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">P-tau181</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.049</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.050</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.047</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.036</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.037</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.033</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.025</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">A<italic toggle="yes">&#x003b2;</italic>42/40</td><td align="left" valign="top" rowspan="1" colspan="1">0.007</td><td align="left" valign="top" rowspan="1" colspan="1">0.395</td><td align="left" valign="top" rowspan="1" colspan="1">0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.455</td><td align="left" valign="top" rowspan="1" colspan="1">0.586</td><td align="left" valign="top" rowspan="1" colspan="1">0.011</td><td align="left" valign="top" rowspan="1" colspan="1">0.187</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.872</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.899</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.002</td><td align="left" valign="top" rowspan="1" colspan="1">0.820</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">P-tau181/A<italic toggle="yes">&#x003b2;</italic>42</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.012</td><td align="left" valign="top" rowspan="1" colspan="1">0.501</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.013</td><td align="left" valign="top" rowspan="1" colspan="1">0.475</td><td align="left" valign="top" rowspan="1" colspan="1">0.586</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.005</td><td align="left" valign="top" rowspan="1" colspan="1">0.801</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.712</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.709</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.749</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">GFAP</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.027</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.028</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.009</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.028</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.009</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.015</td><td align="left" valign="top" rowspan="1" colspan="1">0.123</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.015</td><td align="left" valign="top" rowspan="1" colspan="1">0.108</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.011</td><td align="left" valign="top" rowspan="1" colspan="1">0.331</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">NfL</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.012</td><td align="left" valign="top" rowspan="1" colspan="1">0.274</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.012</td><td align="left" valign="top" rowspan="1" colspan="1">0.242</td><td align="left" valign="top" rowspan="1" colspan="1">0.396</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.006</td><td align="left" valign="top" rowspan="1" colspan="1">0.633</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.015</td><td align="left" valign="top" rowspan="1" colspan="1">0.150</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.016</td><td align="left" valign="top" rowspan="1" colspan="1">0.131</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.007</td><td align="left" valign="top" rowspan="1" colspan="1">0.557</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">PCA1</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.097</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.025</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.102</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>0.019</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.070</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.071</td><td align="left" valign="top" rowspan="1" colspan="1">0.170</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.070</td><td align="left" valign="top" rowspan="1" colspan="1">0.135</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.071</td><td align="left" valign="top" rowspan="1" colspan="1">0.130</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.017</td><td align="left" valign="top" rowspan="1" colspan="1">0.761</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIGH</td><td align="left" valign="top" rowspan="1" colspan="1">PCA2</td><td align="left" valign="top" rowspan="1" colspan="1">0.082</td><td align="left" valign="top" rowspan="1" colspan="1">0.153</td><td align="left" valign="top" rowspan="1" colspan="1">0.077</td><td align="left" valign="top" rowspan="1" colspan="1">0.180</td><td align="left" valign="top" rowspan="1" colspan="1">0.315</td><td align="left" valign="top" rowspan="1" colspan="1">0.090</td><td align="left" valign="top" rowspan="1" colspan="1">0.169</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MIDDLE</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.048</td><td align="left" valign="top" rowspan="1" colspan="1">0.393</td><td align="left" valign="top" rowspan="1" colspan="1">0.046</td><td align="left" valign="top" rowspan="1" colspan="1">0.412</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.037</td><td align="left" valign="top" rowspan="1" colspan="1">0.588</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p id="P71">Abbreviations (units): O-3, omega-3: O-6, omega-6: PUFA, polyunsaturated fatty acid: MUFA, monounsaturated fatty acid: P-tau181, phosphorylated tau 181 level (pg/ml, log10-transformed): A<italic toggle="yes">&#x003b2;</italic>42/40, amyloid-beta 42/40 ratio (log10-transformed): GFAP, glial fibrillary acidic protein level (pg/ml, log10-transformed): NfL, neurofilament light chain level (pg/ml, log10-transformed): PCA1, first principal component (derived from the latter four biomarkers): PCA2, second principal component.</p></fn><fn id="TFN6"><p id="P72">Generalized estimating equations (GEE) were used to evaluate the association of nutrient intake (high and middle compared to low tertiles) with change in biomarker level over time (in visits). Missing values excluded. P-values &#x0003c; 0.05 shown in bold.</p></fn><fn id="TFN7"><label>*</label><p id="P73">Model 1 was adjusted for total energy intake only (<italic toggle="yes">N</italic> = 599 for biomarkers, <italic toggle="yes">N</italic> = 527 for PCAs).</p></fn><fn id="TFN8"><label>&#x02020;</label><p id="P74">Model 2 was adjusted for total energy intake, age, sex, ethnicity, education, and storage time (<italic toggle="yes">N</italic> = 598 for biomarkers, <italic toggle="yes">N</italic> = 526 for PCAs).</p></fn><fn id="TFN9"><label>&#x02021;</label><p id="P75">A trend analysis of Model 2 was performed, using nutrient intake tertile as a continuous integer [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>]. P-values corrected for 21 comparisons using the False Discovery Rate (FDR) are shown.</p></fn><fn id="TFN10"><label>&#x000a7;</label><p id="P76">Model 3 was adjusted for Model 2 covariates plus cardiovascular risk factor (CVRF) score (<italic toggle="yes">N</italic> = 431 for biomarkers, <italic toggle="yes">N</italic> = 374 for PCAs).</p></fn></table-wrap-foot></table-wrap></floats-group></article>